Variable effects of periprostatic adipose tissue on prostate cancer cells: Role of adipose tissue lipid composition and cancer cells related factors.
adipose tissue
epigenetic
fatty acids
prostate cancer
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
19 Dec 2023
19 Dec 2023
Historique:
revised:
28
11
2023
received:
09
07
2023
accepted:
05
12
2023
medline:
19
12
2023
pubmed:
19
12
2023
entrez:
19
12
2023
Statut:
aheadofprint
Résumé
Periprostatic adipose tissue (PPAT) is likely to modulate prostate cancer (PCa) progression. We analyzed the variations in the effect of PPAT on cancer cells, according to its fatty acid (FA) composition and tumor characteristics. The expression of markers of aggressiveness Ki67 and Zeb1, and epigenetic marks that could be modified during PCa progression, was analyzed by immunohistochemistry on a tissue-micro-array containing 59 pT3 PCa, including intra-prostatic areas and extra-prostatic foci in contact with PPAT belonging to the same tumor. In addition, we cocultivated PC3 and LNCaP cell lines with PPAT, which were then analyzed for FA composition. Although the contact between PPAT and cancer cells led overall to an increase in Ki67 and Zeb1, and a decrease in the epigenetic marks 5MC, 5HMC, and H3K27ac, these effects were highly heterogeneous. Increased proliferation in extra-prostatic areas was associated with the international society of uropathology score. PC3 and LNCaP cocultures with PPAT led to increased Ki67, Zeb1 and H3K27me3, but only for PPAT associated with aggressive PCa. PC3 proliferation was correlated with high 20.2 n-6 and low 20.5n-3 in PPAT. These results suggest that the effects of PPAT on cancer cells may depend on both PCa characteristics and PPAT composition, and could lead to propose nutritional supplementation.
Sections du résumé
BACKGROUND
BACKGROUND
Periprostatic adipose tissue (PPAT) is likely to modulate prostate cancer (PCa) progression. We analyzed the variations in the effect of PPAT on cancer cells, according to its fatty acid (FA) composition and tumor characteristics.
METHODS
METHODS
The expression of markers of aggressiveness Ki67 and Zeb1, and epigenetic marks that could be modified during PCa progression, was analyzed by immunohistochemistry on a tissue-micro-array containing 59 pT3 PCa, including intra-prostatic areas and extra-prostatic foci in contact with PPAT belonging to the same tumor. In addition, we cocultivated PC3 and LNCaP cell lines with PPAT, which were then analyzed for FA composition.
RESULTS
RESULTS
Although the contact between PPAT and cancer cells led overall to an increase in Ki67 and Zeb1, and a decrease in the epigenetic marks 5MC, 5HMC, and H3K27ac, these effects were highly heterogeneous. Increased proliferation in extra-prostatic areas was associated with the international society of uropathology score. PC3 and LNCaP cocultures with PPAT led to increased Ki67, Zeb1 and H3K27me3, but only for PPAT associated with aggressive PCa. PC3 proliferation was correlated with high 20.2 n-6 and low 20.5n-3 in PPAT.
CONCLUSIONS
CONCLUSIONS
These results suggest that the effects of PPAT on cancer cells may depend on both PCa characteristics and PPAT composition, and could lead to propose nutritional supplementation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : region center val de loire
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710-1721. doi:10.1016/S0140-6736(08)60729-1
Zhou CK, Check DP, Lortet-Tieulent J, et al. Prostate cancer incidence in 43 populations worldwide: an analysis of time trends overall and by age group. Int J Cancer. 2016;138:1388-1400. doi:10.1002/ijc.29894
Dongre A, Weinberg RA. New insights into the mechanisms of Epithelial-Mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69-84. doi:10.1038/s41580-018-0080-4
Graham TR, Zhau HE, Odero-Marah VA, et al. Insulin-like growth Factor-I-Dependent up-regulation of ZEB1 drives Epithelial-to-Mesenchymal transition in human prostate cancer cells. Cancer Res. 2008;68:2479-2488. doi:10.1158/0008-5472.CAN-07-2559
Figiel S, Vasseur C, Bruyere F, Rozet F, Maheo K, Fromont G. Clinical significance of Epithelial-Mesenchymal transition markers in prostate cancer. Hum Pathol. 2017;61:26-32. doi:10.1016/j.humpath.2016.10.013
Cancel M, Pouillot W, Mahéo K, Fontaine A, Crottès D, Fromont G. Interplay between prostate cancer and adipose microenvironment: A complex and flexible scenario. Int J Mol Sci. 2022;23:10762. doi:10.3390/ijms231810762
Nassar ZD, Aref AT, Miladinovic D, et al. Peri-Prostatic adipose tissue: the metabolic microenvironment of prostate cancer. BJU Int. 2018;121(suppl 3):9-21. doi:10.1111/bju.14173
Figiel S, Pinault M, Domingo I, et al. Fatty acid profile in Peri-Prostatic adipose tissue and prostate cancer aggressiveness in African-Caribbean and caucasian patients. Eur J Cancer. 2018;91:107-115. doi:10.1016/j.ejca.2017.12.017
Figiel S, Bery F, Chantôme A, et al. A novel calcium-mediated EMT pathway controlled by lipids: an opportunity for prostate cancer adjuvant therapy. Cancers. 2019;11:1814. doi:10.3390/cancers11111814
Altuna-Coy A, Ruiz-Plazas X, Sánchez-Martin S, et al. The lipidomic profile of the tumoral periprostatic adipose tissue reveals alterations in tumor cell's metabolic crosstalk. BMC Med. 2022;20:255. doi:10.1186/s12916-022-02457-3
Majumdar S, Buckles E, Estrada J, Koochekpour S. Aberrant DNA methylation and prostate cancer. Curr Genomics. 2011;12:486-505. doi:10.2174/138920211797904061
Zhao Y, Hu X, Yu H, Liu X, Sun H, Shao C. Alternations of gene expression in PI3K and AR pathways and DNA methylation features contribute to metastasis of prostate cancer. Cell Mol Life Sci. 2022;79:436. doi:10.1007/s00018-022-04456-2
Cho NY, Kim BH, Choi M, et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol. 2007;211:269-277. doi:10.1002/path.2106
Yegnasubramanian S, Haffner MC, Zhang Y, et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res. 2008;68:8954-8967. doi:10.1158/0008-5472.CAN-07-6088.
Florl AR, Steinhoff C, Müller M, et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer. 2004;91:985-994. doi:10.1038/sj.bjc.6602030
Goel S, Bhatia V, Biswas T, Ateeq B. Epigenetic reprogramming during prostate cancer progression: a perspective from development. Sem Cancer Biol. 2022;83:136-151. doi:10.1016/j.semcancer.2021.01.009
Margueron R, Reinberg D. The polycomb complex PRC2 and its mark in life. Nature. 2011;469:343-349. doi:10.1038/nature09784
Pardo JC, Ruiz de Porras V, Gil J, Font A, Puig-Domingo M, Jordà M. Lipid metabolism and epigenetics crosstalk in prostate cancer. Nutrients. 2022;14:851. doi:10.3390/nu14040851
Ellinger J, Kahl P, von der Gathen J, et al. Global histone H3K27 methylation levels are different in localized and metastatic prostate cancer. Cancer Invest. 2012;30:92-97. doi:10.3109/07357907.2011.636117
Ngollo M, Lebert A, Daures M, et al. Global analysis of H3K27me3 as an epigenetic marker in prostate cancer progression. BMC Cancer. 2017;17:261. doi:10.1186/s12885-017-3256-y
Labbé DP, Zadra G, Ebot EM, et al. Role of diet in prostate cancer: the epigenetic link. Oncogene. 2015;34:4683-4691. doi:10.1038/onc.2014.422
Huang Q, Wen J, Chen G, et al. Omega-3 polyunsaturated fatty acids inhibited tumor growth via preventing the decrease of genomic DNA methylation in colorectal cancer rats. Nutr Cancer. 2016;68:113-119. doi:10.1080/01635581.2016.1115526
Attané C, Estève D, Moutahir M, Reina N, Muller C. A protocol for human bone marrow adipocyte isolation and purification. STAR Protocols. 2021;2:100629. doi:10.1016/j.xpro.2021.100629
Fontaine A, Bellanger D, Guibon R, Bruyère F, Brisson L, Fromont G. Lipophagy and prostate cancer: association with disease aggressiveness and proximity to periprostatic adipose tissue. J Pathol. 2021;255:166-176. doi:10.1002/path.5754
Lysaght J, van der Stok EP, Allott EH, et al. Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. Cancer Lett. 2011;312:62-72. doi:10.1016/j.canlet.2011.07.034
Laurent V, Guérard A, Mazerolles C, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun. 2016;7:10230. doi:10.1038/ncomms10230
Finley DS, Calvert VS, Inokuchi J, et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol. 2009;182:1621-1627. doi:10.1016/j.juro.2009.06.015
Roche J, Nasarre P, Gemmill R, et al. Global decrease of histone H3K27 acetylation in ZEB1-Induced epithelial to mesenchymal transition in lung cancer cells. Cancers. 2013;5:334-356. doi:10.3390/cancers5020334
Byles V, Zhu L, Lovaas JD, et al. SIRT1 induces EMT by cooperating with EMT transcription factors and enhances prostate cancer cell migration and metastasis. Oncogene. 2012;31:4619-4629. doi:10.1038/onc.2011.612
Takayama K, Misawa A, Suzuki T, et al. TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun. 2015;6:8219. doi:10.1038/ncomms9219
Kaneko A, Satoh Y, Tokuda Y, Fujiyama C, Udo K, Uozumi J. Effects of adipocytes on the proliferation and differentiation of prostate cancer cells in a 3-D culture model. Int J Urol. 2010;17:369-376. doi:10.1111/j.1442-2042.2010.02472.x
Storebjerg TM, Strand SH, Høyer S, et al. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. Clin Epigenetics. 2018;10:105. doi:10.1186/s13148-018-0540-x
Laurent V, Toulet A, Attané C, et al. Periprostatic adipose tissue favors prostate cancer cell invasion in an Obesity-Dependent manner: role of oxidative stress. Mol Cancer Res. 2019;17:821-835. doi:10.1158/1541-7786.MCR-18-0748
Woo S, Cho JY, Kim SY, Kim SH. Periprostatic fat thickness on MRI: correlation with gleason score in prostate cancer. Am J Roentgenol. 2015;204:W43-W47. doi:10.2214/AJR.14.12689
Roumiguié M, Estève D, Manceau C, et al. Periprostatic adipose tissue displays a chronic hypoxic state that limits its expandability. Am J Pathol. 2022;192:926-942. doi:10.1016/j.ajpath.2022.03.008
Ribeiro RJT, Monteiro CPD, Cunha VFPM, et al. Tumor Cell-Educated periprostatic adipose tissue acquires an aggressive Cancer-Promoting secretory profile. Cell Physiol Biochem. 2012;29:233-240. doi:10.1159/000337604
Fatma Karaman E, Caglayan M, Sancar-Bas S, Ozal-Coskun C, Arda-Pirincci P, Ozden S. Global and region-specific post-transcriptional and post-translational modifications of bisphenol A in human prostate cancer cells. Environ Pollut. 2019;255:113318. doi:10.1016/j.envpol.2019.113318.
Treas JN, Tyagi T, Singh KP. Effects of chronic exposure to arsenic and estrogen on epigenetic regulatory genes expression and epigenetic code in human prostate epithelial cells. PLoS One. 2012;7(8):e43880. doi:10.1371/journal.pone
Massillo C, Dalton GN, Porretti J, et al. CTBP1/CYP19A1/Estradiol axis together with adipose tissue impacts over prostate cancer growth associated to metabolic syndrome. Int J Cancer. 2019;144:1115-1127. doi:10.1002/ijc.31773
Bery F, Cancel M, Chantôme A, et al. The Calcium-Sensing receptor is A marker and potential driver of neuroendocrine differentiation in prostate cancer. Cancers (Basel). 2020;12:860. doi:10.3390/cancers12040860
Bilodeau JF, Gevariya N, Larose J, et al. Long chain Omega-3 fatty acids and their oxidized metabolites are associated with reduced prostate tumor growth. Prostagland Leukotr Essent Fatty Acids. 2021;164:102215. doi:10.1016/j.plefa.2020.102215
Gevariya N, Lachance G, Robitaille K, et al. Omega-3 eicosapentaenoic acid reduces prostate tumor vascularity. Mol Cancer Res. 2021;19:516-527. doi:10.1158/1541-7786.MCR-20-0316
Lin X, Lécuyer L, Liu X, et al. Plasma metabolomics for discovery of early metabolic markers of prostate cancer based on ultra-high-performance liquid chromatography-high resolution mass spectrometry. Cancers. 2021;13:3140. doi:10.3390/cancers13133140
Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002;419:624-629.